As of June 15, 2025, Yubo International Biotech Ltd (YBGJ) reports a Net Margin of -197.64%.
Net Margin shows the share of revenue that becomes profit after all costs, reflecting overall profitability.
Historical Trend of Yubo International Biotech Ltd's Net Margin
Over recent years, Yubo International Biotech Ltd's Net Margin has shown a stable trend. The table below summarizes the historical values:
| Date | Net Margin |
|---|---|
| 2023-12-31 | -197.64% |
| 2022-12-31 | -1155.53% |
| 2021-12-31 | -124.19% |
This fluctuation highlights how Yubo International Biotech Ltd manages its overall profitability and cost control over time.
Comparing Yubo International Biotech Ltd's Net Margin to Peers
To better understand Yubo International Biotech Ltd's position, it's useful to compare its Net Margin against industry peers. Below are selected comparisons:
| Company | Net Margin |
|---|---|
| Yubo International Biotech Ltd (YBGJ) | -197.64% |
| First Trust New Opportunities MLP & Energy Fund (FPL) | 290.63% |
| Putnam Master Intermediate Income Trust (PIM) | 200.00% |
| Ellsworth Growth and Income Fund Ltd (ECF) | 114.95% |
| Rivernorth Opportunistic Municipal Income Fund Inc (RMI) | 113.79% |
| BlackRock Long Term Municipal Advantage Trust (BTA) | 109.09% |
Compared to its competitors, Yubo International Biotech Ltd's Net Margin is among the lowest compared to peers, which may indicate challenges in controlling expenses or competitive pricing pressures.